Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial

Gut

Volumn 52, Issue 7, 2003, Pages 998-1002

  Probert, C S J ^a   Hearing, S D ^a   Schreiber, S ^b   Kuhbacher T ^b   Ghosh, S ^c   Arnott, I D R ^c   Forbes, A ^d  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INFLIXIMAB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MEDICAL RECORD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; REMISSION; SCORING SYSTEM; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0038460945     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.7.998     Document Type: Article

References (33)

1. Travis SPL, Farrant JM, Nolan DJ, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
2. Hearing SD, Norman M, Probert CSJ, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocyte. Gut 1999;45:382-8.
3. Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 2001;64:201-4.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
5. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisol? Eur J Gastroenterol Hepatol 1998;10:411-13.
6. Haslam N, Hearing SD, Probert CSJ. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000;12:657-60.
7. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17.
8. MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
9. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
10. Reinecker HC, Steffen M, Witthoett T, et al. Enhanced secretion of tumor-necrosis- factor alpha, IL-6, and IL-1-BETA by isolated lamina propria mononuclear-cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
11. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;349:1398-405.
13. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
14. Arnott IDR, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-46.
15. Nikolaus S, Raedler A, Kuhbacher T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
16. Scallon BJ, Moore MA, Trinth H, et al. Chimeric anti-TNF-alpha monoclonal- antibody CA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
17. Schmidt M, Luegering N, Luegering A, et al. Infliximab exerts anti-inflammatory capacity in IBD by induction of apoptosis in monocytes. Gastroenterology 2000;118(suppl 2):3630.
18. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
19. Ward PS, Woodger SR, Bodmer M, Foulkes R. Anti-tumour necrosis factor alpha monoclonal antibodies are therapeutically effective in a model of colonic inflammation. Br J Pharmacol 1993;110:77P.
20. Watkins PE, Warren BF, Stephens S, et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-33.
21. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-5.
22. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 1987;317:1625-9.
24. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964;i:89-92
25. Irvine EJ. A quality-of-life index for inflammatory bowel disease. Can J Gastroenterol 1993;7:155-9.
26. Williams A for EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
27. Hanauer SB. Medical therapy for ulcerative colitis. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th edn. Philadelphia: W B Saunders, 2000.
28. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
29. Kaser A, Marringer T, Voel T, et al. Infliximab in severe steroid-refractory ulcerative colitis: A pilot study. Wien Kiln Wochenschr 2001;113:930-33.
30. Kohn A, Prantera C, Pera A, et al. Anti-tumour necrosis factor (Infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34:626-30.
31. Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid- refractory ulcerative colitis. Dig Liver Dis 2002;34:631-4.
32. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84.
33. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.